Melphalan Macure (Melphalan)

Melphalan belongs to the alkylating agent class. It creates covalent bonds between DNA strands, forming cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The specific dose and schedule of Melphalan Macure are determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area and overall health. Only a qualified healthcare professional should set the dosing regimen.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided due to potential infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Compared with other alkylating agents, melphalan offers a well‑established efficacy profile in multiple myeloma and certain solid tumours. Some newer agents may have different toxicity spectra, but melphalan remains a standard option, especially when combined with other drugs in multi‑agent regimens.

Melphalan Macure should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and keep it in the original packaging until preparation for infusion.

The drug is supplied as a sterile injectable solution that must be reconstituted according to the manufacturer’s instructions. It is then administered intravenously, typically over a short infusion period, under the supervision of qualified medical personnel.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, and renal impairment. Patients should be closely monitored for blood counts, lung function and kidney parameters throughout therapy.

Melphalan is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, in pregnant women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with pre‑existing renal or pulmonary disease.